Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders


GBT (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product candidate is voxelotor (formerly known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believes inhibits hemoglobin polymerization in sickle cell disease.


Year Invested: 2012
Location: South San Francisco, Calif.
Visit: www.gbt.com/

Recent News

December 7, 2018
Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering

December 6, 2018
Global Blood Therapeutics Announces Proposed Public Offering of Common Stock

December 4, 2018
GBT Announces New Employment Inducement Grants

Read More News

Associated Team Members

Kevin Starr
Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.
Partner

Glenn Pierce, M.D., Ph.D.
Entrepreneur-in-Residence